Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports

In AP syndrome (APS) with severe thrombocytopenia, rituximab represents a unique drug which can balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies, rituximab can simultaneously raise the platelets and reduce the chance of thrombosis by suppressing APL antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamoudi, Donia, Cutajar, Melanie, Gamoudi, Nadia, Camilleri, David James, Gatt, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458029/
https://www.ncbi.nlm.nih.gov/pubmed/28588823
http://dx.doi.org/10.1002/ccr3.946
_version_ 1783241667423240192
author Gamoudi, Donia
Cutajar, Melanie
Gamoudi, Nadia
Camilleri, David James
Gatt, Alex
author_facet Gamoudi, Donia
Cutajar, Melanie
Gamoudi, Nadia
Camilleri, David James
Gatt, Alex
author_sort Gamoudi, Donia
collection PubMed
description In AP syndrome (APS) with severe thrombocytopenia, rituximab represents a unique drug which can balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies, rituximab can simultaneously raise the platelets and reduce the chance of thrombosis by suppressing APL antibodies. Rituximab can supersede splenectomy as second‐line therapy in similar patients.
format Online
Article
Text
id pubmed-5458029
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54580292017-06-06 Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports Gamoudi, Donia Cutajar, Melanie Gamoudi, Nadia Camilleri, David James Gatt, Alex Clin Case Rep Case Reports In AP syndrome (APS) with severe thrombocytopenia, rituximab represents a unique drug which can balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies, rituximab can simultaneously raise the platelets and reduce the chance of thrombosis by suppressing APL antibodies. Rituximab can supersede splenectomy as second‐line therapy in similar patients. John Wiley and Sons Inc. 2017-04-18 /pmc/articles/PMC5458029/ /pubmed/28588823 http://dx.doi.org/10.1002/ccr3.946 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Gamoudi, Donia
Cutajar, Melanie
Gamoudi, Nadia
Camilleri, David James
Gatt, Alex
Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title_full Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title_fullStr Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title_full_unstemmed Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title_short Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
title_sort achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458029/
https://www.ncbi.nlm.nih.gov/pubmed/28588823
http://dx.doi.org/10.1002/ccr3.946
work_keys_str_mv AT gamoudidonia achievingasatisfactoryclinicalandbiochemicalresponseinantiphospholipidsyndromeandseverethrombocytopeniawithrituximabtwocasereports
AT cutajarmelanie achievingasatisfactoryclinicalandbiochemicalresponseinantiphospholipidsyndromeandseverethrombocytopeniawithrituximabtwocasereports
AT gamoudinadia achievingasatisfactoryclinicalandbiochemicalresponseinantiphospholipidsyndromeandseverethrombocytopeniawithrituximabtwocasereports
AT camilleridavidjames achievingasatisfactoryclinicalandbiochemicalresponseinantiphospholipidsyndromeandseverethrombocytopeniawithrituximabtwocasereports
AT gattalex achievingasatisfactoryclinicalandbiochemicalresponseinantiphospholipidsyndromeandseverethrombocytopeniawithrituximabtwocasereports

Ejemplares similares